Accord Aims At Addiction With Buprenorphine Implant Deal
Agreement Sees Firm Distribute Sixmo For Molteni Farmaceutici In Europe
Accord is kicking off plans to launch a number of addiction treatments by partnering with Molteni Farmaceutici on distributing its Sixmo six-month buprenorphine implant in Europe.
You may also be interested in...
Molteni Farmaceutici/Titan’s Sixmo, the first six-month buprenorphine implant just approved for EU marketing, could be a valued option for a sizeable number of patients.
A flurry of financial appointments has been seen across the off-patent industry, involving major players Dr Reddy’s, Biocon, Mayne Pharma and Xbrane Biopharma.
Shanghai Henlius Biotech has struck a co-development and licensing deal with fellow Chinese firm Essexor biosimilar bevacizumab to treat ophthalmic diseases.